RhumbLine Advisers
DMTX

RhumbLine Advisers’s Dimension Therapeutics, Inc DMTX Stock Holding History

RhumbLine Advisers’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,694
Closed -$40K – 3047
2017
Q1 		$40K Buy
22,694
+12,667
+126% +$33.6K ﹤0.01% 2832
2016
Q4 		$44K Sell
10,027
-1,748
-15% -$9.3K ﹤0.01% 2836
2016
Q3 		$94K Buy
+11,775
New +$85.1K ﹤0.01% 2815

Other funds holding DMTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

RhumbLine Advisers's DMTX Position: Q2 2017 in Review

RhumbLine Advisers sold out of Dimension Therapeutics, Inc (DMTX) in Q2 2017, closing a stake of 22,694 shares — an estimated $40K sold.

RhumbLine Advisers first reported a position in DMTX in Q3 2016 and held it in 3 quarters. The position peaked at $94K in Q3 2016. 35 funds tracked by Wall St. Rank hold DMTX as of Q2 2017.

  • RhumbLine Advisers reported no remaining Dimension Therapeutics, Inc position as of Q2 2017 after selling out during the quarter.
  • RhumbLine Advisers sold 22,694 Dimension Therapeutics, Inc shares in Q2 2017, an estimated $40K.
  • RhumbLine Advisers first reported a position in Dimension Therapeutics, Inc in Q3 2016 and held it in 3 quarters.
  • RhumbLine Advisers's Dimension Therapeutics, Inc position peaked at $94K in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.